Edit |   |
---|---|
Antigenic Specificity | LAG3, Human (Ieramilimab biosimilar) |
Clone | Ieramilimab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | n/a |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human LAG3 Recombinant Antibody. Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525. |
Immunogen | n/a |
Other Names | Anti-LAG3 Recombinant Antibody, Research Grade Ieramilimab, Anti-Human LAG3 Recombinant Antibody, LAG-525, Antibody Drug Analogues, Monoclonal Antibody, YR1554, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 2137049-37-5 |
Catalog # | YR1554 |
Price | please inquire |
Order / More Info | LAG3, Human (Ieramilimab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |